#News ⚡ A groundbreaking, worldwide clinical trial that aims to find safer, shorter, effective treatment for multidrug-resistant tuberculosis has completed its enrollment target. #EndTB Partners In Health IRD Global bit.ly/3vr2Pyl

#BREAKING: MSF International is presenting new #tuberculosis trial results The Union Conference #UnionConf    TB-PRACTECAL found a 6-month all-oral regimen is more effective & safer at treating drug-resistant tuberculosis than the current accepted standard of care bit.ly/3DWYJkz

As we commemorate #WorldTBday, MSF International, Partners In Health , IRD Global and Unitaid are pleased to announce the completion of enrollment for the endTB-Q trial, a significant milestone in the fight against #TB. Find out more: bit.ly/3ZcyfWC #endTB

More than six years ago, the endTB clinical trial was launched to find shorter, more tolerable, injection-free treatments for people with #MDRTB. Join us at the #Unionconf2023 in Paris for the endTB clinical trial results presentation! IRD Global MSF International Partners In Health Unitaid

Don’t miss out on the Symposium on the endTB clinical trial results tomorrow at the #UnionConf2023! 10:15 am Paris time, Room 252AB MSF Science Partners In Health IRD Global Unitaid

Join us today at 6pm CET at the #UnionConf Community Connect session where researchers will share the #endTB trial results with communities! MSF Science IRD Global Partners In Health Unitaid

.IRD Global MSF International Partners In Health , and funder Unitaid would like thank all those who attended the endTB clinical trial results presentations at the #UnionConf this week! Safe travels home and stay tuned!

Premiering now: MASSIVE tuberculosis news. youtube.com/watch?v=T-Xdob…

Joining hands for #WTBDay 2024, the endTB trial community met at IRD’s Community Dissemination Event. They celebrated their contribution in advancing knowledge for the treatment of MDR-TB. Partners In Health MSF International Unitaid #irdglobal #tuberculosis 1/2.

On this #WorldTBDay24 , join #endTB in celebrating last year’s achievements in the fight against multidrug-resistant #tuberculosis. Check out our latest news and results: endtb.org/news-stories and endtb.org/endtb-clinical… MSF France IRD Global Partners In Health Unitaid UC San Francisco

Save the date! 🚀 The MSF Scientific Days Southern Africa 2024 are starting tomorrow, Wed. April 17. We thank Dr. Kunda Mikanda, Principal Investigator of the endTB Clinical Trials site in Lesotho, who will present the results of the trial on improving the treatment of MDR-TB.

The @EndTB trial results increase patient-centred treatment options for RR/MDR-TB with three shortened, all-oral, noninferior regimens to a current well-performing standard of care. #MSFSciDaysSA2024 More details 👉msfsa.me/3vZYMh9

🌟 Exciting news! Today at #ESCMIDGlobal2024, Dr. Lorenzo Guglielmetti, Director of the #endTB project, will be presenting a groundbreaking comparison of efficacy and safety between experimental regimens for MDR-TB from the endTB clinical trial (Hall H, 13:30-15:30).

🌟Join us on May 23, for #EpicentreScientificDay! Maelenn Gouillou, Biostatistician of the endTB project, will present findings on drug-resistant tuberculosis subgroups from the #endTB clinical trial. Don't miss it at 2:15pm at Salons de l'Aveyron in Paris. More info here👇🏾

The endTB consortium partners are happy to report that the last visit for the last study participant in the endTB-Q trial was completed on 22 July! Read more: bit.ly/3Sm1oy0 MSF Science Partners In Health IRD Global Unitaid

📢 Breaking news: in a rapid communication, the WHO recommended 3 new, shorter, more tolerable regimens for MDR/RR-TB, which were studied in the endTB clinical trial! More details 👉bit.ly/4fUAsPS MSF Science Partners In Health IRD Global Unitaid